Intellia Therapeutics (NTLA) Projected to Post Earnings on Thursday

Intellia Therapeutics (NASDAQ:NTLA) will likely be posting its Q1 2026 results before the market opens on Thursday, May 14th. Analysts expect Intellia Therapeutics to post earnings of ($0.92) per share and revenue of $13.8060 million for the quarter. Individuals may visit the the company’s upcoming Q1 2026 earning results page for the latest details on the call scheduled for Thursday, May 14, 2026 at 8:00 AM ET.

Intellia Therapeutics (NASDAQ:NTLA) last announced its earnings results on Thursday, February 26th. The company reported ($0.83) EPS for the quarter, beating the consensus estimate of ($0.99) by $0.16. Intellia Therapeutics had a negative return on equity of 56.81% and a negative net margin of 609.85%.The business had revenue of $23.02 million during the quarter, compared to the consensus estimate of $12.17 million. During the same period in the prior year, the business posted ($1.27) earnings per share. Intellia Therapeutics’s revenue was up 78.4% compared to the same quarter last year. On average, analysts expect Intellia Therapeutics to post $-4 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Intellia Therapeutics Stock Up 4.1%

Shares of NASDAQ NTLA opened at $13.85 on Thursday. Intellia Therapeutics has a 12 month low of $6.83 and a 12 month high of $28.25. The company has a market cap of $1.67 billion, a price-to-earnings ratio of -3.62 and a beta of 1.93. The business has a fifty day simple moving average of $13.65 and a 200-day simple moving average of $12.49.

Wall Street Analyst Weigh In

Several equities research analysts have recently commented on the company. HC Wainwright upped their target price on Intellia Therapeutics from $25.00 to $30.00 and gave the company a “buy” rating in a report on Tuesday, March 3rd. Morgan Stanley upped their target price on Intellia Therapeutics from $11.00 to $15.00 and gave the company an “equal weight” rating in a report on Monday, April 27th. Wall Street Zen raised Intellia Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, March 7th. reaffirmed a “buy” rating on shares of Intellia Therapeutics in a report on Tuesday, March 3rd. Finally, KeyCorp set a $25.00 target price on Intellia Therapeutics in a report on Wednesday, January 28th. One investment analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, ten have issued a Hold rating and three have assigned a Sell rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus target price of $20.09.

Institutional Investors Weigh In On Intellia Therapeutics

Several hedge funds have recently bought and sold shares of NTLA. AQR Capital Management LLC lifted its stake in Intellia Therapeutics by 154.1% in the 1st quarter. AQR Capital Management LLC now owns 90,875 shares of the company’s stock worth $646,000 after acquiring an additional 55,118 shares in the last quarter. Woodline Partners LP purchased a new stake in Intellia Therapeutics in the 1st quarter worth about $171,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its stake in Intellia Therapeutics by 8.0% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 521,706 shares of the company’s stock worth $3,709,000 after acquiring an additional 38,521 shares in the last quarter. Creative Planning lifted its stake in Intellia Therapeutics by 12.9% in the 2nd quarter. Creative Planning now owns 33,102 shares of the company’s stock worth $310,000 after acquiring an additional 3,795 shares in the last quarter. Finally, Cetera Investment Advisers lifted its stake in Intellia Therapeutics by 47.4% in the 2nd quarter. Cetera Investment Advisers now owns 33,532 shares of the company’s stock worth $315,000 after acquiring an additional 10,785 shares in the last quarter. 88.77% of the stock is owned by hedge funds and other institutional investors.

About Intellia Therapeutics

Intellia Therapeutics, Inc (NASDAQ: NTLA) is a clinical‐stage biotechnology company focused on developing potentially curative genome editing therapies using the CRISPR/Cas9 platform. The company’s research spans both in vivo and ex vivo applications of CRISPR/Cas9, aiming to correct or disable disease‐causing genes with a single administration. Intellia’s lead in vivo program targets transthyretin amyloidosis (ATTR) by delivering CRISPR/Cas9 machinery directly to the liver, while additional preclinical efforts pursue treatments for hemophilia A, hereditary angioedema and other genetic disorders.

Beyond its in vivo pipeline, Intellia collaborates with strategic partners to extend the impact of its genome editing approach.